Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2618028 | 0.87 | PTGDR (0.38) | SMN1; SMN2EPHX2HDAC4HDAC2HDAC8 | |
| SCHEMBL12253349 | 0.87 | PTGDR (0.38) | SMN1; SMN2EPHX2HDAC4HDAC2HDAC8 | |
| SCHEMBL12304889 | 0.72 | EPHX1 (0.41) | SMN1; SMN2EPHX2NPC1EPHX1RAB9A | |
| SCHEMBL17421883 | 0.72 | ALDH1A1 (0.31) | RAB9A | |
| SCHEMBL17421881 | 0.72 | ALDH1A1 (0.31) | RAB9A | |
| SCHEMBL17421885 | 0.72 | ALDH1A1 (0.31) | RAB9A | |
| SCHEMBL23568273 | 0.71 | MTNR1A (0.37) | SMN1; SMN2EPHX2HDAC6NPC1EPHX1 | |
| SCHEMBL11145308 | 0.70 | EPHX1 (0.42) | EPHX2CYP19A1NPC1EPHX1 | |
| SCHEMBL16204627 | 0.70 | EPHX1 (0.42) | EPHX2CYP19A1NPC1EPHX1 | |
| SCHEMBL11145822 | 0.70 | EPHX1 (0.42) | EPHX2CYP19A1NPC1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256831-A1 | HYDROGEL AND METHOD FOR PRODUCING SAME | THE UNIVERSITY OF TOKYO (JP) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256831-A1 | HYDROGEL AND METHOD FOR PRODUCING SAME | CD44, CSGALNACT1, CDC37 | THRA 2089/4885THRB 3229/4885SMN1; SMN2 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.